This morning, Pfizer / BioNTech he surrendered data from the Food and Drug Administration from its evaluation of the Covid vaccine for children, introducing a method that can give doses to children between 5 and 11 in the next month or two.
It is the cases of children who are on the rise – last week, under the age of 18 made up about 27% of the cases recently reported, according to the American Academy of Pediatrics, even though they represent only 22% of the US population – there is strong pressure to change the law immediately. But parents who have been expecting a lot this time around may find more obstacles in their way than they expected. As a matter of fact, getting a vaccine was just one of many challenges to protecting children. Sharing and sharing is also difficult, too.
First, a new shot will arrive in the system already filled. “Vaccine programs do not have the time to think about the group, because they have been working on adult vaccines, as well as the number of anti-influenza drugs, which cannot be delayed,” said Kelly Moore, a doctor and president and CEO of a nonprofit organization people at Vaccination. “She can’t breathe, which is a problem, because it’s coming fast.”
But this shot will also be given to children in different places, perhaps by different people, than the main vaccine released last winter. They have arrived in a country with more politics than ever before. And it is unknown at this time what he will do after leaving the post just this morning find that 45 percent of parents do not plan to vaccinate their young children.
A review where we are on the shoot with the kids. Let us point out, first of all, that all of these plans only involve Pfizer / BioNTech, the only manufacturer whose experiments have been advanced to make it possible for children to be vaccinated. Their vaccine has been approved by the FDA permanently since August, but only 16 years of age; for 12 to 15 children, the vaccine remains intact, and children under 12 have never received it.
Pfizer has been following clinical trials The goal is to introduce the vaccine to young children from March. About 4,500 children in the test were divided into three groups: 6 months to 23 months; 2 years to under 5; and 5 to 11. In each group, the vaccine tested is a small fraction of the adult drug, ranging from one to one. Last week, the company made its first comment on it test results for children, stating that two-thirds of the three were able to get the same treatment in the ages of 5 to 11 as the two full rates of 16- to 25-year-olds. This is the result, and more, of what the company brought to the FDA today. Most of those under 5 years of age should follow.
(Some manufacturers have not yet tested it. Moderna vaccine is licensed for emergency use between the ages of 18 and beyond, and is awaiting full approval from adults with a license for young people. The company has started training for children under 12 years of age. in August. J&J, a single-drug vaccine, is the one that prompts the other two companies to do research; has an emergency permit that only applies to adults.)
Since last summer, Pfizer, moderators, and business analysts are all have been said that he expects the first permit to arrive by the end of October or November. That comparison still looks solid, if it has any anticipation. The timing is ridiculous, because no one outside the FDA knows how quickly the agency will review what could be difficult to extinguish, useful, security and its consequences. Two independent committees, the FDA’s advisers and the Centers for Disease Control and Prevention, should evaluate later, and no one outside their group can say how to carefully review this. (These are the two committees that met in the last two weeks discuss and in the end agree temporary shooting of the American people.)
Source link
